Wegovy

Weight Watchers Expands Collaboration With Novo Nordisk

July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the […]

Weight Watchers Expands Collaboration With Novo Nordisk Read More »

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report

News / John LaRosa

Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »

Zepbound Beats Wegovy for Weight Loss

News / John LaRosa

Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists

Zepbound Beats Wegovy for Weight Loss Read More »

23 and me To Enter The Weight Loss Market

News / John LaRosa

August 13, 2024 As reported by Fiercehealthcare.com today in an article… The genetic testing company 23andMe sees an opportunity to get in on the weight loss boom. The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with

23 and me To Enter The Weight Loss Market Read More »

Employers and Insurers Push Back on GLP-1 Drugs Coverage

News / John LaRosa

June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the

Employers and Insurers Push Back on GLP-1 Drugs Coverage Read More »

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs

News / John LaRosa

March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »

Semaglutide Boom – The Beginning of a Decline? New FDA Report

News / John LaRosa

January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market

Semaglutide Boom – The Beginning of a Decline? New FDA Report Read More »

Obesity Drug Sales Continue To Soar

News / John LaRosa

Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In

Obesity Drug Sales Continue To Soar Read More »

Semaglutide Gold Rush Is On, Compounding Pharmacies

News, Uncategorized / John LaRosa

June 5, 2023 There is no doubt that the new obesity drugs (Wegovy, Ozempic) are hot and in high demand, but there is a disturbing new trend developing. Since the brand name drugs often cost $1,000 to $1,300 per month and are not covered by insurance, people are looking for cheaper alternatives. That’s where compounding

Semaglutide Gold Rush Is On, Compounding Pharmacies Read More »

Noom Is Testing Weight Loss Drugs

News, Uncategorized / John LaRosa

April 19, 2023 We obtained some information regarding Noom’s participation in the medical weight loss arena. “…Noom Clinical is offered to adults (18+) that are over BMI 30 or, BMI 27 and above with obesity-related conditions. Individual eligibility for specific options is determined by our trained clinicians and overseen by our Chief of Medicine. With

Noom Is Testing Weight Loss Drugs Read More »

(813) 971-8080